Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

VERA THERAPEUTICS, INC.

(VERA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/16/2021 09/17/2021 09/20/2021 09/21/2021 09/22/2021 Date
22.48(c) 20.93(c) 17.75(c) 16.36(c) 15.92 Last
271 520 911 600 158 831 173 318 134 257 Volume
-26.54% -6.90% -15.19% -7.83% -2.69% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 - - -
Net income 2021 -34,8 M - -
Net Debt 2021 - - -
P/E ratio 2021 -6,62x
Yield 2021 -
Sales 2022 - - -
Net income 2022 -51,2 M - -
Net Debt 2022 - - -
P/E ratio 2022 -5,63x
Yield 2022 -
Capitalization 348 M 348 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 -
Nbr of Employees 13
Free-Float 96,2%
More Financials
Company
Vera Therapeutics, Inc. is a clinical stage biotechnology company. The Company is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a biologic inhibitor of B cells and plasma cells. Atacicept is self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator (BLyS) and a... 
More about the company
All news about VERA THERAPEUTICS, INC.
09/09VERA THERAPEUTICS : Hosting Key Opinion Leader Webinar on IgA Nephropathy
AQ
08/16VERA THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Result..
AQ
08/16VERA THERAPEUTICS : Reports Second Quarter 2021 Financial Results and Provides Corporate U..
PU
08/16VERA THERAPEUTICS, INC. : Results of Operations and Financial Condition, Financial Stateme..
AQ
08/16Vera Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate ..
GL
08/16Vera Therapeutics, Inc. Reports Unaudited Earnings Results for the Second Quarter and S..
CI
07/14VERA THERAPEUTICS : Employment Terms (Form 8-K)
PU
07/14VERA THERAPEUTICS, INC. : Change in Directors or Principal Officers, Financial Statements ..
AQ
07/14VERA THERAPEUTICS : Taps Sean Grant for Finance Chief
MT
07/14Vera Therapeutics Appoints Sean Grant as Chief Financial Officer
GL
07/14Vera Therapeutics, Inc. Appoints Sean Grant as Chief Financial Officer
CI
06/24VERA THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Result..
AQ
06/24VERA THERAPEUTICS, INC. : Results of Operations and Financial Condition, Financial Stateme..
AQ
06/24Vera Therapeutics, Inc. Reports Unaudited Earnings Results for the First Quarter Ended ..
CI
06/24Vera Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate U..
GL
More news
News in other languages on VERA THERAPEUTICS, INC.

- No features available -

More news
Analyst Recommendations on VERA THERAPEUTICS, INC.
More recommendations
Chart VERA THERAPEUTICS, INC.
Duration : Period :
Vera Therapeutics, Inc. Technical Analysis Chart | VERA | US92337R1014 | MarketScreener
Technical analysis trends VERA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 16,36 $
Average target price 26,00 $
Spread / Average Target 58,9%
EPS Revisions
Managers and Directors
Marshall W. Fordyce President, Chief Executive Officer & Director
Sean P. Grant Chief Financial Officer
Konrad Hans von Emster Chairman
Celia Lin Chief Medical Officer
Tom Doan Senior Vice President-Development Operations
Sector and Competitors
1st jan.Capi. (M$)
VERA THERAPEUTICS, INC.0.00%348
MODERNA, INC.315.47%175 199
LONZA GROUP AG33.09%60 866
IQVIA HOLDINGS INC.43.03%49 103
CELLTRION, INC.-23.26%31 708
SEAGEN INC.-5.78%30 021